In December 2012, a Cochrane Review brought together the results of clinical trials that had looked at the effects of blood-clot promoting drugs on patients who were bleeding. The review was dominated by the large, CRASH-2 trial. In this podcast, Mike Clarke speaks with Ian Roberts, from the London School of Hygiene and Tropical Medicine in England, about both the trial and the review.<img src="http://feeds.feedburner.com/~r/PodcastsFromTheCochraneLibrary/~4/wkT_aQZ9D0k" height="1" width="1" alt=""/>

In December 2012, a Cochrane Review brought together the results of clinical trials that had looked at the effects of blood-clot promoting drugs on patients who were bleeding. The review was dominated by the large, CRASH-2 trial. In this podcast, Mike Clarke speaks with Ian Roberts, from the London School of Hygiene and Tropical Medicine in England, about both the trial and the review.

In December 2012, a Cochrane Review brought together the results of clinical trials that had looked at the effects of blood-clot promoting drugs on patients who were bleeding. The review was dominated by the large, CRASH-2 trial. In this podcast, Mike Clarke speaks with Ian Roberts, from the London School of Hygiene and Tropical Medicine in England, about both the trial and the review.

CRASH-2

Cochrane produces systematic reviews which are recognized as the highest standard in evidence-based health care resources. Listen to Cochrane review authors explain in plain language the evidence and findings of their high-impact reviews. In 5 minutes or less, healthcare professionals to patients and families can understand the latest trusted evidence to help make better informed decisions.

Share CRASH-2

Sign up to save your podcasts

CRASH-2

CRASH-2